• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Horizon, Boehringer Ingelheim enter oncology research service collaboration

Horizon, Boehringer Ingelheim enter oncology research service collaboration

January 14, 2013
CenterWatch Staff

Horizon Discovery, a provider of research tools to support the development of personalized medicines has signed a research service collaboration agreement with Germany-based Boehringer Ingelheim.

Horizon will support Boehringer Ingelheim’s oncology programs by using its Discovery Toolbox for research projects and profiling of compounds at the hit-to-lead, lead optimization and preclinical stages to elucidate their anti-cancer properties and help guide drug discovery programs. Horizon will evaluate compounds across a broad panel of X-MAN isogenic models and selected 2D/3D phenotypic assays, and will provide an FTE and access to its custom cell line generation services to support the programs.

Horizon will also apply its proprietary genome editing technology GENESIS to develop human isogenic disease model cell lines, according to Boehringer Ingelheim’s specifications. Using GENESIS, Horizon is able to alter any endogenous gene sequence of human or mammalian cell lines quickly, reliably and without unwanted and confounding genotypes and/or phenotypes. The resulting high quality cell lines accurately model the disease-causing mutations found in patients.

“We are delighted that Boehringer Ingelheim has selected Horizon as a partner for its drug discovery programs, in recognition of the value our X-MAN cell lines and drug discovery services can add to the search for novel treatments for cancer,” said Kam Dhaliwal, vice president of sales, Horizon.

Financial terms of the agreement were not disclosed.

Upcoming Events

  • 25Apr

    Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

  • 26Apr

    FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

  • 27Apr

    Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

  • 17May

    2023 WCG Avoca Quality Consortium Summit

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • tablet

    Digital Intake Platforms Effective as Source of Trial Information, Survey Shows

  • Diversity-360x240.png

    Site Spotlight: EmVenio Research Takes to the Road to Promote Trial Diversity

  • Five Ws

    Consider the Five ‘W’s to Understand Potential Participants

  • QandA-360x240.png

    Perspectives from Smaller-Sized CROs: Q&A with Cheryle Evans

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing